Expanding horizons of anticoagulant therapy: Dabigatran etexilate a novel oral anticoagulant.
Loading...
Date
2013-09
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Thrombo-embolic disease is a major challenging clinical problem associated with significant mortality and morbidity. Anticoagulation with the existing heparin products and vitamin K antagonist (VKA) anticoagulants are still the mainstay of management. However, due to the risk of bleeding and well-documented drawbacks, the quest for a novel oral anticoagulant has led to the clinical development of dabigatran etexilate. Dabigatran etexilate is a direct thrombin (IIa) inhibitor which has recently been approved in India for prevention of venous thromboembolic events (VTE) in patients who have undergone major orthopaedic (total knee or hip replacement) surgery and for prevention of stroke, systemic embolism and reduction of vascular mortality in adult patients with atrial fibrillation. Thus dabigatran etexilate is a promising alternative to the current heparin products and VKAs in patients who require long-term oral anticoagulation.
Description
Keywords
Dabigatran etexilate, Direct thrombin inhibitor, Novel anticoagulant, Stroke prevention, Atrial fibrillation, Venous thromboembolism, Orthopaedic surgery
Citation
Jadhav Pradeep, Ray Ipseeta, Vieira Alfven, Ghanekar Jaishree, Deshmukh Yeshwant A. Expanding horizons of anticoagulant therapy: Dabigatran etexilate a novel oral anticoagulant. International Journal of Basic & Clinical Pharmacology. 2013 Sep-Oct; 2(5): 663-667.